Examine Maximum Tolerated Dose and Pharmacokinetic and Pharmacodynamic Profile
Open label, single dose and phase I study.

The primary objective: To determine the maximum tolerated dose in Single dose

The secondary objective: to evaluate the toxicity in administration to determine desirable dosing amount for phase II to evaluate tumor response in progressive solid cancer patients to evaluate pharmacokinetic/ pharmacodynamic profile.
Solid Tumour
DRUG: CG200745
To determine the maximum tolerated dose in Single dose, On 22 days after administration
1. Number of Subjects: 28\~36, dose escalation (2\~6 subject of each step)
2. Adverse Events will be coded to preferred therm and body system using the CTCAE